Ascendis Pharma Presents 3-Year Data At ASBMR 2024 Showing Long-Term Treatment With TransCon PTH Normalizes Bone Remodeling In Adults With Hypoparathyroidism
Ascendis Pharma在ASBMR 2024展示了爲期3年的數據,表明TransCon PTH的長期治療使甲狀旁腺功能減退成人的骨重塑恢復正常
Ascendis Pharma Presents 3-Year Data At ASBMR 2024 Showing Long-Term Treatment With TransCon PTH Normalizes Bone Remodeling In Adults With Hypoparathyroidism
Ascendis Pharma在ASBMR 2024展示了爲期3年的數據,表明TransCon PTH的長期治療使甲狀旁腺功能減退成人的骨重塑恢復正常
使用瀏覽器的分享功能,分享給你的好友吧